1-3 of 3
Laurent Poulain
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids

Mégane Vernon, Bernard Lambert, Matthieu Meryet-Figuière, Emilie Brotin, Louis-Bastien Weiswald, Hippolyte Paysant, Nicolas Vigneron, Anaïs Wambecke, Edwige Abeilard, Florence Giffard, Marie-Hélène Louis, Cécile Blanc-Fournier, Pascal Gauduchon, Laurent Poulain, Christophe Denoyelle
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (7): 1506–1519.
https://doi.org/10.1158/1535-7163.MCT-19-0510
Published: 02 July 2020
View article titled, Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids
Open the PDF for Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids in another window
Includes: Supplementary data
Journal Articles

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737

Cécile Pétigny-Lechartier, Charlène Duboc, Abdelghani Jebahi, Marie-Hélène Louis, Edwige Abeilard, Christophe Denoyelle, Pascal Gauduchon, Laurent Poulain, Marie Villedieu
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (1): 102–115.
https://doi.org/10.1158/1535-7163.MCT-16-0342
Published: 05 January 2017
View article titled, The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737
Open the PDF for The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737 in another window
Includes: Supplementary data
Journal Articles

Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells

Karin Simonin, Emilie Brotin, Sandrine Dufort, Soizic Dutoit, Didier Goux, Monique N'Diaye, Christophe Denoyelle, Pascal Gauduchon, Laurent Poulain
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (11): 3162–3170.
https://doi.org/10.1158/1535-7163.MCT-09-0493
Published: 10 November 2009
View article titled, Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells
Open the PDF for Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells in another window